ABOUT ENHERTU

Woman at beach holding shells

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

  • human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.
  • HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

Woman at beach holding shells

How is ENHERTU thought to work?

As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.

Antibody graphic Antibody graphic

ENHERTU is made up of an antibody with the chemotherapy attached

Antibody and cancer cell graphic Antibody and cancer cell graphic

The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell

Cancer cell graphic Cancer cell graphic

ENHERTU enters the cancer cell and the chemotherapy is released

Destroy cancer cell graphic Destroy cancer cell graphic

The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby

Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.

If you have not yet received a treatment for HER2-positive metastatic breast cancer, ENHERTU can work with pertuzumab to target HER2 cancer cells.

How will I receive ENHERTU?

ENHERTU and pertuzumab are given as intravenous (IV) infusions once every 3 weeks.

You will receive your ENHERTU and pertuzumab infusions either at your oncologist's office or at a nearby infusion center.

Pill icon

Your healthcare provider will give you
medicines before your infusions to
help prevent nausea and vomiting.

First infusion – 90 and 60 minutes

The first infusion of ENHERTU in combination with pertuzumab will take roughly 2.5 hours, with approximately 30 minutes between infusions, so your healthcare provider can monitor for any potential reactions.

Your ENHERTU infusion will take about 90 minutes and your pertuzumab infusion will take about 60 minutes.

Future infusions – 30 minutes

Future ENHERTU and pertuzumab infusions should take about 30 to 60 minutes each if your first infusions were well tolerated.

You will receive ENHERTU and pertuzumab until your cancer has gotten worse or when you can no longer tolerate treatment.

If you miss a planned dose of ENHERTU with pertuzumab, call your healthcare provider right away to schedule an appointment.
Do not wait until the next planned treatment cycle.

ENHERTU is given as an intravenous (IV) infusion once every 3 weeks.

You will receive an ENHERTU infusion either at your oncologist's office or at a nearby infusion center.

Pill icon

Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.

First infusion – 90 and 60 minutes

The first ENHERTU infusion will take about 90 minutes so the healthcare provider can monitor for any potential reactions.

Future infusions – 30 minutes

Future ENHERTU infusions should take about 30 minutes if your first infusion was well tolerated.

If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment.
Do not wait until the next planned treatment cycle.

Support and resources icon

Understand the results of two ENHERTU clinical trials

Review results
Sign up for information email

Financial support and downloadable resources

Learn about ENHERTU4U

HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.